Genprex Inc. (NASDAQ: GNPX) maintained upside momentum in yesterday’s session, and closed the day with gains of 23.44%. This came after news that, independent researchers had found the company’s TUSC2 to be a possible novel biomarker for treating thyroid cancer. The